EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that James Hoyes has been appointed President of EMD Serono. In this capacity, he will be responsible for driving the strategic direction of the US commercial organization as well as managing the day-to-day business of the US affiliate of Merck KGaA. Mr. Hoyes will also serve as a member of the Executive Management Board for Merck Serono, the global pharmaceuticals division of Merck KGaA.
"Jim's experience, leadership and vision will add significant value to our US operations," said Dr. Stefan Oschmann, Member of the Executive Board of Merck KGaA and President of Merck Serono. "He has a strong knowledge of the industry and expertise across a variety of commercial functions, including sales, marketing, communications, managed markets, and collaborations. We are confident that Jim will enhance the reputation of EMD Serono as a leader in biopharmaceuticals in the US." Mr. Hoyes previously served as Chief Commercial Officer for EMD Serono, responsible for business operations in the company's key therapeutic areas of neurodegenerative diseases, rheumatology, fertility and metabolic endocrinology, as well as managed care, business intelligence, health outcomes, specialty pharmacy and commercial operations.
"I look forward to working with our leadership teams and our employees in continuing to provide patients with important treatments and services, to delivering successful business outcomes, and to driving medical advancements through research and development," says Mr. Hoyes. "The people of EMD Serono are incredibly talented and passionate about our purpose of making a difference in society and in the lives of patients, and I am proud to be a part of this team." Mr. Hoyes also led the neurology franchise at EMD Serono, managing the operations of sales, marketing, communications, call center operations, and medical affairs. He joined EMD Serono in February 2004 as Vice President of Marketing in neurology.
Prior to joining EMD Serono, Mr. Hoyes gained experience in a variety of commercial roles of increasing responsibilities at Elan, Sanofi and Sterling Drug. Mr. Hoyes also has extensive experience working in a partnership environment (such as co-promotion and joint venture agreements) with other biopharmaceutical companies such as Pfizer, BMS, UCB and Wyeth.
Mr. Hoyes graduated from the Pennsylvania State University with a Bachelor of Science in Biology.